Trial Profile
A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary) ; Glycerol phenylbutyrate (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 04 Mar 2022 Status changed from recruiting to discontinued.
- 11 Mar 2021 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.
- 11 Mar 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2022.